T
Thaminda Liyanage
Researcher at The George Institute for Global Health
Publications - 11
Citations - 1966
Thaminda Liyanage is an academic researcher from The George Institute for Global Health. The author has contributed to research in topics: Kidney disease & Renal function. The author has an hindex of 7, co-authored 9 publications receiving 1405 citations. Previous affiliations of Thaminda Liyanage include Memorial Hospital of South Bend & Royal North Shore Hospital.
Papers
More filters
Journal ArticleDOI
Worldwide access to treatment for end-stage kidney disease: a systematic review.
Thaminda Liyanage,Thaminda Liyanage,Toshiharu Ninomiya,Vivekanand Jha,Vivekanand Jha,Vivekanand Jha,Bruce Neal,Halle Marie Patrice,Ikechi G. Okpechi,Ming hui Zhao,Jicheng Lv,Amit X. Garg,John Knight,Anthony Rodgers,Martin Gallagher,Sradha Kotwal,Alan Cass,Alan Cass,Vlado Perkovic,Vlado Perkovic +19 more
TL;DR: The large number of people receiving RRT and the substantial number without access to it show the need to both develop low-cost treatments and implement effective population-based prevention strategies.
Journal ArticleDOI
Effects of the Mediterranean Diet on Cardiovascular Outcomes-A Systematic Review and Meta-Analysis.
Thaminda Liyanage,Thaminda Liyanage,Toshiharu Ninomiya,A. Wang,Bruce Neal,Min Jun,Min Jun,Muh Geot Wong,Muh Geot Wong,Meg Jardine,Meg Jardine,Graham S. Hillis,Vlado Perkovic +12 more
TL;DR: The Mediterranean diet may protect against vascular disease, however, both the quantity and quality of the available evidence is limited and highly variable.
Journal ArticleDOI
Effects of fibrates in kidney disease: a systematic review and meta-analysis
Min Jun,Bin Zhu,Marcello Tonelli,Meg Jardine,Anushka Patel,Bruce Neal,Thaminda Liyanage,Anthony C Keech,Alan Cass,Vlado Perkovic +9 more
TL;DR: It is suggested that fibrates have a place in reducing cardiovascular risk in people with mild-to-moderate CKD and reduce albuminuria and reversibly increase serum creatinine but the effects on major kidney outcomes remain unknown.
Journal ArticleDOI
Worldwide Access to Treatment for End-Stage Kidney Disease: A Systematic Review
TL;DR: Worldwide use of RRT is projected to more than double to 5·439 million (3·899–7·640 million) people by 2030, with the most growth in Asia and Africa and the largest treatment gaps in low-income countries, particularly Asia.
Journal ArticleDOI
Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis.
Bin Zhu,Ying Wang,Meg Jardine,Min Jun,Jicheng Lv,Jicheng Lv,Alan Cass,Thaminda Liyanage,Hongyu Chen,Yong-jun Wang,Vlado Perkovic +10 more
TL;DR: Tripterygium preparations may have nephroprotective effects, but high-quality trials are required to reliably determine the balance of benefits and harms, according to a random-effects model.